Cargando…

Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy

SIMPLE SUMMARY: Mantle Cell Lymphoma (MCL) is a lymphoproliferative disorder which represents less than 10% of all non-Hodgkin Lymphomas. The typical course of MCL is characterized by several relapses (“remitting-relapsing” course), and since its identification it has been considered an incurable di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marangon, Miriam, Visco, Carlo, Barbui, Anna Maria, Chiappella, Annalisa, Fabbri, Alberto, Ferrero, Simone, Galimberti, Sara, Luminari, Stefano, Musuraca, Gerardo, Re, Alessandro, Zilioli, Vittorio Ruggero, Ladetto, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7830938/ https://www.ncbi.nlm.nih.gov/pubmed/33466784 http://dx.doi.org/10.3390/cancers13020291

Ejemplares similares

S221: LONG-TERM RESULTS OF THE FIL MCL0208 TRIAL COMPARING LENALIDOMIDE MAINTENANCE (LEN) VS OBSERVATION (OBS) AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MANTLE CELL LYMPHOMA (MCL)
por: Ladetto, Marco, et al.
Publicado: (2023)

Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial
por: Ferrero, Simone, et al.
Publicado: (2023)

Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term
por: Cortelazzo, Sergio, et al.
Publicado: (2021)

CAR T-Cell therapy for the management of mantle cell lymphoma
por: Huang, Zoufang, et al.
Publicado: (2023)

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
por: Mohty, Razan, et al.
Publicado: (2022)

Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma
por: Ferrero, Simone, et al.
Publicado: (2022)

Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
por: Beitinjaneh, Amer, et al.
Publicado: (2022)

Recent Advances in Allogeneic CAR-T Cells
por: Kim, Dong Wook, et al.
Publicado: (2020)

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
por: Galimberti, S, et al.
Publicado: (2010)

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma
por: Martínez Bedoya, Darel, et al.
Publicado: (2021)

Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)
por: Tbakhi, Bushra, et al.
Publicado: (2022)

CAR T-cell therapy for mantle cell lymphoma with central nervous system relapse
por: Vu, Khoan, et al.
Publicado: (2022)

Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study
por: Morello, Lucia, et al.
Publicado: (2019)

A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia
por: Martino, Massimo, et al.
Publicado: (2021)

A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial
por: Bomben, Riccardo, et al.
Publicado: (2018)

P1081: A MULTICENTER OBSERVATIONAL STUDY ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR LARGE B-CELL (LBCL) AND MANTLE CELL (MCL) LYMPHOMAS: THE ITALIAN CART-SIE REAL LIFE EXPERIENCE
por: Chiappella, Annalisa, et al.
Publicado: (2023)

Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study
por: Chiappella, Annalisa, et al.
Publicado: (2023)

Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma
por: Genuardi, Elisa, et al.
Publicado: (2021)

Tackling Mantle Cell Lymphoma in Europe
por: Horgan, Denis, et al.
Publicado: (2022)

TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2022)

Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation
por: Shanbhag, Satish, et al.
Publicado: (2010)

Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma
por: Broccoli, Alessandro, et al.
Publicado: (2018)

Allogeneic CAR-T Cells: More than Ease of Access?
por: Graham, Charlotte, et al.
Publicado: (2018)

Strategies for overcoming bottlenecks in allogeneic CAR-T cell therapy
por: Lv, Zixin, et al.
Publicado: (2023)

Mantle cell lymphoma patients in first relapse: we pretty much know what to do
por: Quaglia, Francesca Maria, et al.
Publicado: (2021)

The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy
por: Castagna, Luca, et al.
Publicado: (2022)

Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
por: Liu, Jun, et al.
Publicado: (2017)

Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma
por: Heini, Alexander D., et al.
Publicado: (2022)

BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma—Finding a Dancing Partner
por: Munoz, Javier L., et al.
Publicado: (2022)

Straightforward Generation of Ultrapure Off-the-Shelf Allogeneic CAR-T Cells
por: Juillerat, Alexandre, et al.
Publicado: (2020)

P1245: CLINICAL IMPACT OF IMMUNOGLOBULIN HEAVY CHAIN REPERTOIRE IN MANTLE CELL LYMPHOMA: A STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (FIL) PHASE III MCL0208 TRIAL.
por: Alessandria, B., et al.
Publicado: (2022)

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
por: Zurko, Joanna, et al.
Publicado: (2022)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

Lenalidomide in Diffuse Large B-Cell Lymphomas
por: Chiappella, Annalisa, et al.
Publicado: (2012)

Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Analysis in the Rituximab Era
por: Mussetti, Alberto, et al.
Publicado: (2015)

Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience
por: Gutierrez, Antonio, et al.
Publicado: (2022)

A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy
por: Valton, Julien, et al.
Publicado: (2015)

Allogeneic CAR Cell Therapy—More Than a Pipe Dream
por: Caldwell, Kenneth J., et al.
Publicado: (2021)

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022)

An Alternative Source for Allogeneic CAR T Cells With a High Safety Profile
por: Wu, Xiaolong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n6cs2d7v9ktgk7ikpiv6k1cb8l